BiotechTube

BMB-101 + Placebo

Phase 2Recruiting
0 watching 0 views this week⚡ Active
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Prader-Willi Syndrome

Conditions

Prader-Willi Syndrome

Trial Timeline

Jan 1, 2026 → Mar 1, 2027

NCT ID
NCT07266324

About BMB-101 + Placebo

BMB-101 + Placebo is a phase 2 stage product being developed by Bright Minds Biosciences for Prader-Willi Syndrome. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07266324. Target conditions include Prader-Willi Syndrome.

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT07266324Phase 2Recruiting
NCT05397041Phase 1Completed

Competing Products

18 competing products in Prader-Willi Syndrome

See all competitors
ProductCompanyStageHype Score
Octreotide + PlaceboNovartisPre-clinical
23
Norditropin SimpleXxNovo NordiskPre-clinical
22
somatropin - GH naïve pediatric cohort + somatropin - GH treated cohort + somatropin - adult cohortPfizerPhase 3
76
Setmelanotide + PlaceboRhythm PharmaceuticalsPhase 2
49
SetmelanotideRhythm PharmaceuticalsPhase 2
49
RGH-706 + PlaceboRichter GedeonPhase 2
49
CarbetocinAcadia PharmaceuticalsPhase 3
72
Carbetocin + PlaceboAcadia PharmaceuticalsPhase 3
72
DCCRSoleno TherapeuticsPhase 3
72
DCCR + DCCR + Placebo for DCCRSoleno TherapeuticsPhase 3
72
PitolisantHarmony BiosciencesPhase 3
72
Pitolisant tabletHarmony BiosciencesPhase 3
72
Pitolisant oral tablets + Placebo oral tabletHarmony BiosciencesPhase 2
47
DCCRSoleno TherapeuticsPhase 3
72
VYKAT XRSoleno TherapeuticsPre-clinical
18
DCCR + Placebo for DCCRSoleno TherapeuticsPhase 3
72
NNZ-2591Neuren PharmaceuticalsPhase 2
47
ARD-101Aardvark TherapeuticsPhase 2
44

Other Products from Bright Minds Biosciences

BMB-101Phase 2
47
BMB-101 + PlaceboPhase 1
28